Both in Biotechnology
Lineage Cell Therapeutics vs Fate Therapeutics
Over the past year LCTX returned −42.8% and FATE returned +75.6%; their daily moves had a correlation of 0.27.
LCTX −42.8% FATE +75.6%Growth of $1, one year, split-adjusted
| Metric | LCTX | FATE |
|---|---|---|
| Price | $1.03 | $2.09 |
| Market cap | $260.5M | $250.4M |
| Today | +1.98% | +2.45% |
| 1 month | +9.8% | −8.7% |
| 6 months | −28.0% | −8.7% |
| Year to date | −38.3% | +112.7% |
| 1 year | −47.4% | +65.9% |
| Revenue growth (YoY) | −61.3% | +9.2% |
| Gross margin | 100.0% | 100.0% |
| Net margin | 138.6% | −1448.6% |
| P/E (TTM) | — | — |
| Price / sales | 19.9× | 38.6× |
| Net cash | $50.8M | $153.8M |
| Dividend yield | — | — |
| Volatility (60d) | 52.5% | 56.4% |
| Short % of float | 12.9% | 10.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).